What is the appropriate tapering regimen for bupropion (Wellbutrin) 150 mg daily in a patient experiencing hallucinations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Discontinue Wellbutrin Immediately Due to Hallucinations

Bupropion (Wellbutrin) should be stopped immediately when a patient experiences hallucinations, as this represents a serious neuropsychiatric adverse effect. The FDA drug label explicitly instructs providers to "discontinue use if these signs occur" when serious neuropsychiatric issues develop 1, 2.

Discontinuation Protocol

For patients on 150 mg daily, taper to discontinuation is not required per FDA labeling. The official Wellbutrin XL prescribing information states: "When discontinuing treatment in patients treated with Wellbutrin XL 300 mg once daily, decrease the dose to 150 mg once daily prior to discontinuation" 2. This guidance only applies to patients on 300 mg doses—patients already on 150 mg can discontinue directly without further tapering 2.

Immediate Management Steps:

  • Stop bupropion 150 mg immediately without tapering
  • Monitor closely for 2 weeks as withdrawal symptoms typically peak within 1-2 weeks of cessation 1
  • Consider short-term antipsychotic therapy if hallucinations persist after discontinuation—risperidone has been successfully used in case reports of bupropion-induced psychosis 3
  • Reassess within 1 week to confirm resolution of psychotic symptoms

Clinical Context and Safety Considerations

The development of hallucinations on bupropion is uncommon but well-documented. Research shows hallucinations occur in approximately 0.4% of patients taking extra doses 4, though they can occur at therapeutic doses, particularly in vulnerable populations 5, 3, 6. Bupropion's dopaminergic effects are the likely mechanism for inducing psychotic symptoms 7, 8.

Key Safety Points:

Hallucinations represent a contraindication to continued bupropion use. The NCCN guidelines emphasize that providers should "monitor for the development or worsening of serious neuropsychiatric issues (ie, depression and suicidal ideation/behavior), including those without a previous history, and discontinue use if these signs occur" 1.

Do not attempt dose reduction as an alternative to discontinuation. While dose adjustments may be appropriate for other side effects like insomnia or dry mouth 9, hallucinations require complete cessation 1, 2.

Symptoms typically resolve within one week of discontinuation when combined with appropriate antipsychotic coverage if needed 3. One case series documented complete resolution of bupropion-induced psychotic symptoms within 7 days after drug withdrawal and risperidone initiation 3.

Alternative Treatment Considerations

After hallucinations resolve, consider alternative antidepressants with different mechanisms of action:

  • SSRIs or SNRIs (sertraline, escitalopram, duloxetine) have lower risk of psychotic symptoms
  • Avoid rechallenge with bupropion—case reports document recurrence of psychosis upon reintroduction even at lower doses 5
  • Screen for underlying risk factors including substance use history, prior head trauma, or undiagnosed psychotic spectrum disorders before initiating any new antidepressant 3

Related Questions

As the primary care physician, how should I manage a female patient on bupropion (Wellbutrin) who for the past week has experienced increased fatigue, emotional lability, panic symptoms, tension‑type headaches, and diarrhea?
Should the provider reduce the bupropion (Wellbutrin) dose for a patient who regularly consumes alcohol?
Should I continue bupropine in a patient who refuses to reduce alcohol consumption?
A female patient started on bupropion (Wellbutrin) is experiencing nausea and abdominal pain; should she continue the medication?
What are the indications, dosing schedule, contraindications, side effects, and monitoring recommendations for bupropion hydrochloride extended‑release?
What is the appropriate management for a hyperplastic gastric polyp containing focal intestinal metaplasia in an adult patient (≥50 years)?
What dose of vaginal micronized progesterone is recommended for uterine‑lining thickening during the luteal phase in a reproductive‑age woman?
How should I explain to a patient with a hyperplastic gastric polyp containing intestinal metaplasia the need for H. pylori testing, eradication therapy (PPI plus amoxicillin and clarithromycin or metronidazole if penicillin‑allergic), repeat endoscopy in 3–6 months, possible polyp removal if >1 cm or symptomatic, and the follow‑up surveillance schedule?
What are the clinical implications of sertraline's sigma‑1 receptor agonism, α‑adrenergic receptor down‑regulation, and benzodiazepine receptor modulation?
What is the recommended management when the gastric biopsy shows no Helicobacter pylori?
What are the contraindications for using GLP‑1 receptor agonists in patients with chronic kidney disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.